Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Source:

Nursing2015

November 2005, Volume 35 Number 11 , p 30 - 30

Authors

Abstract

In a study of 20,000 patients experiencing acute coronary syndrome in 41 countries, the newer anticoagulant fondaparinux (Arixtra) proved just as effective as enoxaparin (Lovenox) at preventing blood clots while cutting the risk of bleeding by half. Bleeding is the most serious adverse reaction associated with anticoagulants.

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: